A Phase 1 interventional study of Lipitor Tab. 40mg and Trilipix 135mg in Healthy, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-08.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the pharmacokinetic interaction between Atorvastatin and Fenofibric acid.
This study is a randomized, open-label, multiple dosing, 3-way crossover design to evaluate the drug-drug interaction between Atorvastatin (Lipitor) and Fenofibric (Trilipix) acid in healthy male subjects. Subjects will receive repeated dose of Atorvastatin (40mg*1Tab/day) or Fenofibric acid (135mg*1Cap/day) or Atorvastatin (40mg*1Tab/day)/Fenofibric acid (135mg*1Cap/day). Each treatment period was separated by a washout period of at least 8 days.
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg
TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg
TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg
TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg
TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg
TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
Drug: Lipitor Tab. 40mg · Drug: Trilipix 135mg
Also known as: Atorvastatin 40mg
Also known as: Fenofibric acid 135mg
Atorvastatin and Fenofibric acid AUCτ
1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points
Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks
Atorvastatin and Fenofibric acid Css,max
1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points
Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks
Atorvastatin and Fenofibric acid Css,min
1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points
Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks
Atorvastatin and Fenofibric acid Css,av
1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points
Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks
2-hydroxyatorvastatin AUCτ
1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points
Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks
2-hydroxyatorvastatin Css,max
1D\~7D 19points, 1D\~7D 18points, 1D\~7D 20points
Time frame: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours post-dose, an expected average of 6weeks
Ran from Mar 2015 to primary completion in Mar 2015, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Choline fenofibrate
Chong Kun Dang Pharmaceutical →